ProPhase Labs, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
ProPhase Labs, Inc. (PRPH) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $38.52 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-06-01.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-06-01
- ProPhase Labs, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $6.07, a 31.10% decline year-over-year.
- ProPhase Labs, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $8.81.
- ProPhase Labs, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2022-03-31 was $8.99.
- ProPhase Labs, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2019-03-31 was $2.35.
- ProPhase Labs, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $38.52, a 48.51% decline from fiscal 2024.
- ProPhase Labs, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $74.81, a 765.86% increase from fiscal 2023.
- ProPhase Labs, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $8.64, a 453.85% increase from fiscal 2022.
- ProPhase Labs, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $1.56.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $38.52 10-K · filed 2026-06-01 | ||||
| 2025-09-30 | $3.85 10-Q · filed 2025-11-19 | ||||
| 2025-06-30 | $6.06 10-Q · filed 2025-08-13 | ||||
| 2025-03-31 | $6.07 10-Q · filed 2025-05-20 | ||||
| 2024-12-31 | $74.81 10-K · filed 2026-06-01 | $7.48 10-K · filed 2025-04-01 | |||
| 2024-09-30 | $7.53 10-Q · filed 2024-11-13 | ||||
| 2024-06-30 | $7.97 10-Q · filed 2024-08-14 | ||||
| 2024-03-31 | $8.81 10-Q · filed 2024-05-10 | ||||
| 2023-12-31 | $8.64 10-K · filed 2025-04-01 | $0.64 10-K · filed 2024-03-29 | |||
| 2022-12-31 | $1.56 10-K · filed 2024-03-29 | ||||
| 2022-09-30 | $2.02 10-Q · filed 2022-11-10 | ||||
| 2022-06-30 | $2.87 10-Q · filed 2022-08-12 | ||||
| 2022-03-31 | $8.99 10-Q · filed 2022-05-13 | ||||
| 2019-06-30 | $2.87 10-Q · filed 2019-08-12 | ||||
| 2019-03-31 | $2.35 10-Q · filed 2019-05-14 | ||||
| 2017-12-31 | $1.00 10-K/A · filed 2018-08-20 | ||||
| 2016-12-31 | $1.44 10-K/A · filed 2018-08-20 | ||||
| 2015-12-31 | $13.50 10-K/A · filed 2018-08-20 | ||||
| 2014-12-31 | $9.50 10-K · filed 2017-02-24 | ||||
| 2013-12-31 | $4.53 10-K · filed 2016-03-29 | ||||
| 2012-12-31 | $8.11 10-K · filed 2015-03-27 | ||||
| 2011-12-31 | $8.67 10-K · filed 2014-03-27 | ||||
| 2010-12-31 | $9.45 10-K · filed 2013-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |